Letter by Iguchi and Nango Regarding Article, “Pioglitazone for Secondary Stroke Prevention: A Systematic Review and Meta-Analysis”
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
To the Editor:
We would like to commend Lee et al1 for their excellent article. Their systematic review and meta-analysis of pioglitazone for secondary stroke prevention is meaningful because the field of diabetes mellitus research recognizes the importance of analysis of significant clinical outcomes, including heart disease and mortality, rather than surrogate markers as the end point of diabetes mellitus drug analysis.2 A previous Cochrane Review showed that intensive glycemic control did not reduce stroke incidence in type 2 diabetes mellitus.3 However, we have a concern about their analysis and interpretation.
As the authors pointed out, the data derived from PROactive …